121 related articles for article (PubMed ID: 8280709)
1. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
Shu S; Sussman JJ; Chang AE
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):279-85. PubMed ID: 8280709
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
4. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
5. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
6. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
[TBL] [Abstract][Full Text] [Related]
8. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
Sakai K; Chang AE; Shu SY
Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
[TBL] [Abstract][Full Text] [Related]
9. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
10. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy.
Yoshizawa H; Sakai K; Chang AE; Shu SY
Cell Immunol; 1991 May; 134(2):473-9. PubMed ID: 1827049
[TBL] [Abstract][Full Text] [Related]
11. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells.
Wahl WL; Sussman JJ; Shu S; Chang AE
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):242-50. PubMed ID: 8061896
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4.
Krauss JC; Strome SE; Chang AE; Shu S
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530
[TBL] [Abstract][Full Text] [Related]
15. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.
Mitsuma S; Yoshizawa H; Ito K; Moriyama H; Wakabayashi M; Chou T; Arakawa M; Shu S
Immunology; 1994 Sep; 83(1):45-51. PubMed ID: 7821965
[TBL] [Abstract][Full Text] [Related]
17. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
Liu J; Finke J; Krauss JC; Shu S; Plautz GE
Cancer Immunol Immunother; 1998 Jul; 46(5):268-76. PubMed ID: 9690455
[TBL] [Abstract][Full Text] [Related]
19. Enhancing effect of interleukin 1 alpha administration on antitumor effector T-cell development.
Sondak VK; Tuck MK; Shu S; Yoshizawa H; Chang AE
Arch Surg; 1991 Dec; 126(12):1503-8; discussion 1508-9. PubMed ID: 1842180
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
Li Q; Yu B; Grover AC; Zeng X; Chang AE
J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
